Quantcast

Industry news that matters to you.  Learn more

Massachusetts General Hospital is Newest SOMAscan Assay Site

SomaLogic, Inc., recently announced that Massachusetts General Hospital (MGH) will be the first Boston-area biomedical research center to perform on-site studies using the SOMAscan™ assay, a breakthrough proteomics platform that can measure more than a thousand proteins in a small amount of blood or other biological sample. The SOMAscan assay will be performed under the direction of Robert Gerszten, MD, Director of Clinical and Translational Research of the MGH Heart Center and Professor of Medicine at Harvard Medical School. It is expected that the SOMAscan assay will be installed and fully functional at MGH by mid-fall of 2014.

Researchers Identify a Metabolite as a Biomarker of Diabetes Risk

Type 2 diabetes (T2D) is the most common form of diabetes and is associated with many complications. T2D is preventable through weight control and exercise; however, many individuals are unaware that they are at risk and do not change their lifestyle in time to avoid disease.

Gene-expression-based Biomarker Predicts Long-term Risk of Breast Cancer Recurrence

A comparison of three methods of predicting the risk of recurrence in women treated for estrogen-receptor (ER)-positive breast cancer finds that only the breast cancer index (BCI) – a biomarker based on the expression levels of seven tumor-specific genes – accurately identifies patients who continue to be at risk after five years of treatment with either tamoxifen or the aromatase inhibitor anastrozole. The study comparing the BCI with two other prognostic tests has been published online in Lancet Oncology.

bioTheranostics’ Breast Cancer IndexSM Molecular Test Identifies Risk for Early and Late Breast Cancer Recurrence, Lancet Oncology Study Finds

A study published online in The Lancet Oncology found that in a comparison of three methods of predicting the risk of recurrence of estrogen-receptor (ER)-positive breast cancer, only the Breast Cancer IndexSM (BCI) from bioTheranostics predicts risk for both early (0-5 years) and late (5-10 years) recurrence. The study provides important new information to guide patient treatment decisions at diagnosis and after several years of therapy.

Study Identifies Fibroblast Growth Factor 18 as an Ovarian Cancer Biomarker

Ovarian cancer is one of the leading causes of cancer-related death in women and is often not detected until the later stages of disease, which contributes to poor prognosis. Biomarkers that can be used for early diagnosis and outcome have been identified; however, many of these have not been evaluated at the biological and clinical levels. In the current issue of the Journal of Clinical Investigation, Michael Birrer and colleagues at Massachusetts General Hospital identify fibroblast growth factor 18 (FGF18) as a predictive marker for poor overall survival in ovarian cancer patients. Overexpression of the gene encoding FGF18 was associated with enhanced tumor blood vessel formation and expression of cancer promoting cytokines. These data indicate that further studies on the predictive potential FGF18 and its use as a therapeutic target in ovarian cancer are warranted.

Study: FGF18 as a prognostic and therapeutic biomarker in ovarian cancer [The Journal of Clinical Investigation]

Source: EurekAlert!